Lineage Cell Therapeutics, Inc. (LCTX) Nonoperating Income (Expense) USD 2010 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2010 to 2024.
  • Lineage Cell Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending March 31, 2024 was $103 K, a 76.3% decline year-over-year.
  • Lineage Cell Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending March 31, 2024 was $1.12 M.
  • Lineage Cell Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $1.45 M.
  • Lineage Cell Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$3.29 M, a 155% decline from 2021.
  • Lineage Cell Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was $5.94 M, a 31.4% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $1.12 M $103 K -$332 K -76.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $1.45 M $1.65 M +$1.37 M +495% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 $80 K -$453 K -$129 K -39.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $209 K -$179 K +$2.37 M +93% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-10
Q1 2023 -$2.16 M $435 K +$1.13 M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$3.29 M $277 K +$50 K +22% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 -$3.34 M -$324 K +$1.68 M +83.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$5.02 M -$2.55 M -$4.66 M -220% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$358 K -$697 K -$6.3 M -112% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $5.94 M $227 K -$6.64 M -96.7% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $12.6 M -$2 M -$778 K -63.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $13.4 M $2.12 M +$2.24 M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $11.1 M $5.6 M +$6.59 M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $4.52 M $6.87 M +$5.33 M +348% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$811 K -$1.23 M +$7.86 M +86.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$8.67 M -$128 K +$20.4 M +99.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$29 M -$990 K -$48.7 M -102% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $19.6 M $1.53 M +$36.8 M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 -$17.1 M -$9.08 M -$86 M -112% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 $68.9 M -$20.5 M -$25 M -555% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $93.8 M $47.7 M +$99.2 M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$5.34 M -$35.2 M +$32.1 M +47.6% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$37.4 M $76.9 M +$48.6 M +172% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$86 M $4.5 M +$12 M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 -$98.1 M -$51.5 M -$114 M -183% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $15.6 M -$67.3 M -$70.7 M -2091% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 $86.3 M $28.3 M -$10.5 M -27.2% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $96.8 M -$7.54 M -$43.2 M -121% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $140 M $62.2 M +$62.4 M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 $77.6 M $3.38 M -$401 K -10.6% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-15
Q3 2016 $78 M $38.8 M +$39.4 M Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $38.6 M $35.6 M +$35.4 M +15458% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $3.19 M -$239 K +$26 K +9.81% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 $3.16 M $3.78 M +$4.34 M Oct 1, 2015 Dec 31, 2015 10-K 2018-03-15
Q3 2015 -$1.18 M -$585 K -$459 K -364% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-04
Q2 2015 -$725 K $229 K +$74 K +47.7% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 -$799 K -$265 K -$326 K -536% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 -$473 K -$563 K -$521 K -1245% Oct 1, 2014 Dec 31, 2014 10-K 2017-03-16
Q3 2014 $47.9 K -$126 K -$71.6 K -132% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-09
Q2 2014 $120 K $155 K +$234 K Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-10
Q1 2014 -$115 K $60.8 K +$89.4 K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-08
Q4 2013 -$204 K -$41.8 K +$52.6 K +55.7% Oct 1, 2013 Dec 31, 2013 10-K 2016-03-15
Q3 2013 -$257 K -$54.4 K -$77.3 K -337% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-07
Q2 2013 -$179 K -$79.2 K -$164 K -193% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-11
Q1 2013 -$15 K -$28.6 K +$290 K +91% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-12
Q4 2012 -$305 K -$94.4 K -$279 K -151% Oct 1, 2012 Dec 31, 2012 10-K 2015-03-11
Q3 2012 -$25.9 K $22.9 K +$27.2 K Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-12
Q2 2012 -$53.1 K $85.1 K +$104 K Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-09
Q1 2012 -$157 K -$319 K -$400 K -493% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-10
Q4 2011 $243 K $185 K Oct 1, 2011 Dec 31, 2011 10-K 2014-03-17
Q3 2011 -$4.25 K +$2.34 M +99.8% Jul 1, 2011 Sep 30, 2011 10-Q 2011-11-08
Q2 2011 -$19.3 K +$19 K +49.6% Apr 1, 2011 Jun 30, 2011 10-Q 2011-08-09
Q1 2011 $81.2 K Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-10
Q3 2010 -$2.34 M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-08
Q2 2010 -$38.4 K Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.